New EU Commission Recommendation for PPE and Medical Devices – COVID-19
PPE and Medical Devices have proven to be essential for healthcare workers in the efforts to contain the COVID-19 outbreak. In March 2020, the EU Commission urged the economic operators to increase rapid supply into the market. Currently, the Commission considers that the conditions for exceptional access to market are no longer met, limiting the placing of PPE and Medical Devices which have not successfully undergone the relevant conformity assessment procedures applicable on the EU market.


In March 2020, the European Commission adopted Recommendation (EU) 2020/403 on conformity assessment and market surveillance procedures within the context of the COVID-19 outbreak. The aim was to allow for the increased supply of Personal Protective Equipment (PPE) and Medical Devices to feed into the market rapidly and without undue delays.

Accordingly, if market surveillance authorities found that conformity assessment procedures (including affixing of CE marking) were not yet finalized, but the PPE or medical device ensured an adequate level of health and safety, they could authorize the making available of such products on the EU market, for a limited period of time and while the necessary procedures were being carried out.

Moreover, PPE or medical devices without CE marking could also be assessed and part of a purchase organized by the relevant Member States. This was merely possible if these products were only available for healthcare workers for the duration of the health crisis and if they were not entering the regular distribution channels and made available for other users.

There was an unprecedented and exponential growth in the demand for medical devices and for PPE, like face masks, gloves, and others. Following this recommendation, EU Economic operators have worked hard on increasing their manufacturing and distribution capacity in order to answer the increased demand, redesigning their supply chains, launching new manufacturing lines and diversifying their supplier base.


In this new Recommendation on conformity assessment and market surveillance procedures within the context of the COVID-19 threat, the Commission concluded, based on information provided by industrial stakeholders and relevant national authorities, that there are no longer any significant shortages of PPE and medical devices on the European market, and it is to be expected that the situation would remain stable. The Commission considers that the underlying conditions justifying the application of Recommendation (EU) 2020/403 are no longer reunited.

Regulation (EU) 2016/425 lays down the requirements for the design, manufacturing and placing on the market of PPE. Particle filtering half-masks, coveralls and eyewear protection fall within the scope of this Regulation.

As for medical devices, such as surgical masks, examination gloves and some types of gowns, the requirements for design, manufacturing and placing on the market are laid down by Regulation (EU) 2017/745.

As happened before the Recommendation (EU) 2020/403, when a manufacturer wants to place a PPE or medical device on the market, it should carry out the applicable conformity assessment procedures and affix the CE marking, if compliance with applicable requirements has been demonstrated by the appropriate procedure. Annex II to Regulation (EU) 2016/245 for PPE and Annex I to Regulation (EU) 2017/745 for medical devices sets the essential performance and safety requirements that these products shall meet so they can be placed on the market and circulate freely across the entire EU market.

PPE and medical devices that were assessed by market surveillance authorities and granted approval decision (according to mechanisms described in point 7 and 8 of Recommendation (EU) 2020/403), have been proven to comply with essential health and safety requirements of Regulation (EU) 2016/425 and Regulation (EU) 2017/745).

The Commission has set a date from which no PPE or medical devices should be made available on the EU market unless it has undergone the mandatory conformity assessment procedures and has been lawfully affixed with the CE marking.

As from 1 October 2021, PPE that have not been successfully undergone the relevant conformity assessment procedures (in accordance with PPE Regulation (EU) 2016/425) should no longer be authorized by market surveillance authorities and cannot be placed on the EU market.

PPE or medical devices that have been granted authorization according to Recommendation (EU) 2020/403 can only be made available until 31 May 2022. Exception is made for products that are part of existing stocks at the disposal of healthcare workers, first responders and other personnel involved in the efforts to contain the virus and avoid its further spread. These stocks may be made available until fully exhausted, but no later than 31 July 2022.

From 1 August 2022, market surveillance authorities should ensure that all PPE or medical devices placed in the EU market have successfully passed the relevant conformity assessment procedures in accordance with Regulation (EU) 2016/245 and Regulation (EU) 2017/745 and bear a lawfully affixed CE marking. For medical devices, such does not apply if specific derogations from the conformity assessment procedure have been authorized by Member States, according to the corresponding Regulation.


  1. Commission Recommendation (EU) 2021/1433 of 1 September 2021 on conformity assessment and market surveillance procedures within the context of the COVID-19 threat.
  2. Commission Recommendation (EU) 2020/403 of 13 March 2020 on conformity assessment and market surveillance procedures within the context of the COVID-19 threat.
  3. Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC.
  4. Regulation (EU) 2016/425 of the European Parliament and of the Council of 9 March 2016 on personal protective equipment and repealing Council Directive 89/686/EEC.


medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »